BackIgene Biotechnology Overview

Igene Biotechnology Total Liabilities

Igene Biotechnology's total liabilities is $8.1M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$8.10M
↑ 0.66% YoYΔ $53044.00 vs prior year quarter

Peer trimmed avg / median

Loading

Igene Biotechnology Total Liabilities History

Loading

Igene Biotechnology vs. peers: Total Liabilities Comparison

Loading

Igene Biotechnology Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Igene Biotechnology (IGNE) FAQ

The latest total liabilities for IGNE is $8.1M as of September 2010. That compares with $8M in the prior-year period — up 0.7% year over year. Investors often review this figure alongside Igene Biotechnology's historical trend and sector peers before judging valuation or financial health.

Over the past year, IGNE's total liabilities moved from $8M to $8.1M — a 0.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Igene Biotechnology's operating scale or balance-sheet position.

A total liabilities figure of $8.1M for IGNE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IGNE's total liabilities ($8.1M), review year-over-year change from $8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.